Positive top-line phase II results of Ofatumumab in MS
Posted: Fri Oct 11, 2013 2:31 am
Genmab A/S announced top-line results from a Phase II study of the subcutaneous formulation of
ofatumumab in relapsing-remitting multiple sclerosis (RRMS).
A total of 232 subjects with RRMS were randomized in the study. There was a
clear separation from placebo on the cumulative number of new gadolinium
enhancing lesions (active brain lesions) over a period of 12 weeks in subjects
treated with all doses of ofatumumab compared to subjects treated with placebo
[p < 0.001]. For the primary endpoint, analysis of data from weeks 0-12
estimated a 65% reduction in the cumulative number of new T1 gadolinium
enhancing lesions for all doses [p < 0.001]. In weeks 4-12, analyses of data
estimated a >= 90% reduction in the cumulative number of new T1 gadolinium
enhancing lesions for all cumulative doses of ofatumumab >= 30 mg [p < 0.001]...... Read More - http://www.ms-uk.org/emergingtherapies
ofatumumab in relapsing-remitting multiple sclerosis (RRMS).
A total of 232 subjects with RRMS were randomized in the study. There was a
clear separation from placebo on the cumulative number of new gadolinium
enhancing lesions (active brain lesions) over a period of 12 weeks in subjects
treated with all doses of ofatumumab compared to subjects treated with placebo
[p < 0.001]. For the primary endpoint, analysis of data from weeks 0-12
estimated a 65% reduction in the cumulative number of new T1 gadolinium
enhancing lesions for all doses [p < 0.001]. In weeks 4-12, analyses of data
estimated a >= 90% reduction in the cumulative number of new T1 gadolinium
enhancing lesions for all cumulative doses of ofatumumab >= 30 mg [p < 0.001]...... Read More - http://www.ms-uk.org/emergingtherapies